AstraZeneca's new anticancer Zactima fails to impress in lung cancer
This article was originally published in Scrip
Executive Summary
Three Phase III trials testing AstraZeneca's new oral targeted anticancer Zactima (vandetanib) as a second-line therapy in non-small cell lung cancer (NSCLC) failed to impress experts at the recent ASCO meeting in Orlando, Florida, who called for the testing of biomarkers which would predict which patients benefited most from the drug.